Loading clinical trials...
Loading clinical trials...
Double-blind, Placebo-controlled, Randomized, Dose-escalating, Multi-center, Phase 1 Study to Assess the Safety and Tolerability of ART-123 With Leucovorin/5-fluorouracil/Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients
Conditions
Interventions
thrombomodulin alfa
Placebo
Locations
32
United States
Beverly Hills Cancer Center
Beverly Hills, California, United States
UCLA Dept. of Medicine - Hematology/Oncology
Los Angeles, California, United States
Eastern Connecticut Hematology & Oncology Associates
Norwich, Connecticut, United States
Mid-Florida Hematology & Oncology Centers
Orange City, Florida, United States
Horizon Oncology Research, Inc.
Lafayette, Indiana, United States
American Oncology Partners, P.A.
Bethesda, Maryland, United States
Start Date
March 24, 2022
Primary Completion Date
June 5, 2024
Completion Date
June 5, 2024
Last Updated
August 19, 2024
NCT07352514
NCT07064798
NCT07164950
NCT06994507
NCT04633655
NCT04970121
Lead Sponsor
Veloxis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions